Takeda Pharmaceutical Company Limited (TAK) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$16.64
Price Target
—
Target Range
— — —
Analyst Rating
Buy
Forward P/E0.2x
Trailing P/E77.4x
Forward PEG0.01
Implied Growth+100.5%
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
Valuation Model TargetsConfidence: 43/100
Bear$2050
Base$4104
Bull$14084
TAK Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Takeda Pharmaceutical Company Limited (TAK) has a Wall Street consensus price target of N/A, based on estimates from 6 covering analysts. The company has a market capitalization of $52.57B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TAK trades at a trailing P/E of 77.4x and forward P/E of 0.2x. The forward PEG ratio of 0.01 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +100.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $4103.55, with bear and bull scenarios of $2050.45 and $14084.09 respectively. Model confidence stands at 43/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+10.2%
Avg Forward P/E13.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVONovo Nordisk A/S | $203.5B | $45.79 | $47.00 | +2.6% | Buy | 2.1x | 39 |
 AZNAstraZeneca PLC | $283.0B | $182.52 | $211.00 | +15.6% | Buy | 17.7x | 41 |
 SNYSanofi | $104.3B | $43.18 | $50.00 | +15.8% | Buy | 10.3x | 27 |
 NVSNovartis AG | $277.4B | $145.39 | $141.00 | -3.0% | Hold | 16.6x | 25 |
 GSKGSK plc | $101.6B | $50.50 | $52.45 | +3.9% | Hold | 10.4x | 29 |
 ABBVAbbVie Inc. | $358.4B | $202.64 | $256.64 | +26.6% | Buy | 14.3x | 41 |
 BMYBristol-Myers Squibb Company | $114.8B | $56.25 | $62.00 | +10.2% | Hold | 8.9x | 41 |
 JNJJohnson & Johnson | $536.2B | $222.51 | $249.27 | +12.0% | Buy | 19.2x | 40 |
 MRKMerck & Co., Inc. | $277.3B | $112.29 | $129.31 | +15.2% | Buy | 21.9x | 37 |
 PFEPfizer Inc. | $150.6B | $26.48 | $27.27 | +3.0% | Hold | 8.9x | 39 |
Upside Potential Comparison
ABBVSNYAZNMRKJNJBMYGSKPFEFull TAK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See TAK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TAK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TAK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTAK — Frequently Asked Questions
Quick answers to the most common questions about buying TAK stock.
What is the TAK stock price target for 2026?
The consensus price target for TAK is $N/A, close to the current price of $16.64 (N/A% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
Is TAK a buy, sell, or hold?
TAK has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is TAK stock overvalued or undervalued?
With a forward P/E of 0.2318x, TAK trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
How high can TAK stock go?
The most bullish Wall Street analyst has a price target of $N/A for TAK, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $14084 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover TAK stock?
TAK is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the TAK stock forecast?
The 12-month TAK stock forecast based on 6 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $4104, with bear/bull scenarios of $2050/$14084.
What is TAK's fair value based on fundamentals?
Our quantitative valuation model calculates TAK's fair value at $4104 (base case), with a bear case of $2050 and bull case of $14084. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.
What is TAK's forward P/E ratio?
TAK trades at a forward P/E ratio of 0.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 77.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy TAK stock?
TAK appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do TAK price targets vary so much?
TAK analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $2050-$14084 range provides an independent fundamental perspective.